Article information
Full text is only aviable in PDF
Bibliografía
[1.]
American Thoracic Society Documents.
AmericanThoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis.
Am J Respir Crit Care Med, 167 (2003), pp. 603-662
[2.]
World Health Organization.
Treatment of tuberculosis.
Guidelines for National Programmes, 3rd ed,
[3.]
D.A. Enarson, H.L. Rieder, T. Arnadottir, A. Trébucq.
Management of tuberculosis.
A guide for low oncome countries, 5th ed,
[4.]
J.A. Caminero Luna.
Guía de la tuberculosis para médicos especialistas,
[5.]
D. Benator, M. Bhattacharya, L. Bozeman, W. Burman, A. Catanzaro, R. Chaisson, et al.
Rifapentine and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial.
Lancet, 360 (2002), pp. 528-534
[6.]
A. Vernon, W. Burman, D. Benator, A. Khan, L. Bozeman.
Adquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid.
Lancet, 353 (1999), pp. 1843-1847
[7.]
American Thoracic Society.
Treatment of tuberculosis and tuberculosis infection in adults and children.
Am J Respir Crit Care Med, 149 (1994), pp. 1359-1374
[8.]
M. Goble, M.D. Iseman, L.A. Madsen, D. Waite, L. Ackerson, R. Horsburgh.
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.
N Engl J Med, 328 (1993), pp. 527-532
[9.]
S.K. Park, C.T. Kim, S.D. Song.
Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.
Int J Tuberc Lung Dis, 2 (1998), pp. 877-884
[10.]
W.A. Geerligs, R. Altena, W.C.M. De Lange, D. Van Soolingen, T.S. Van der Werf.
Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands.
Int J Tuberc Lung Dis, 4 (2000), pp. 758-764
[11.]
A Report from the Research Committee of the British Tuberculosis Association.
Ethionamide, pyrazinamide and cicloserine in the treatment of drug-resistant pulmonary tuberculosis.
Tubercle, 44 (1963), pp. 195-214
[12.]
E. Jancik, M. Zelenka, J. Tousek, M. Makova.
Chemotherapy for patients with cultures resistant to streptmomycin, isoniazid and PAS.
Tubercle, 44 (1963), pp. 443-445
[13.]
P. De March.
Turell. Resultados obtenidos mediante regímenes de asociación con dos o tres drogas secundarias en el retratamiento del tuberculoso pulmonar cronico.
Rev Clin Esp, 109 (1968), pp. 119-126
[14.]
I. Kass.
Chemotherapy regimens used in retreament of pulmonary tuberculosis. I. Observations on the efficacy of combinations of kanamycin, ethionamide and either cycloserine or pyrazinamide.
Tubercle, 46 (1965), pp. 151-165
[15.]
J. Tousek, E. Jancik, M. Zelenca, M. Jancikova-Makova.
The results of treatment in patients with cultures resistant to streptomycin,isoniazid and PAS: a five years follow-up Tubercle, 48 (1967), pp. 27-32
[16.]
D.A. Fischer, W. Lester, W.E. Dye, T.S. Moulding.
Retreatment of patients with isoniazid-resistant tuberculosis: analysis and follow-up of 146 cases.
Amer Rev Resp Dis, 97 (1968), pp. 392-398
[17.]
American Thoracic Society.
Chemotherapy of pulmonary tuberculosis in adults: the choice of drugs in relation to drug susceptibility.
Am Rev Respir Dis, 92 (1965), pp. 508-512
[18.]
American Thoracic Society.
Treatment of drug-resistant tuberculosis.
Am Rev Respir Dis, 94 (1966), pp. 125-127
[19.]
American Thoracic Society.
Medical Section of the American Lung Association. Treatment of tuberculosis and tuberculosis infection in adults and children.
Am Rev Respir Dis, 134 (1986), pp. 355-363
[20.]
N. Martín-Casabona, F. Alcaide, P. Coll, J. González, J.M. Manterola, M. Salvado, et al.
Fármaco resistencia del Mycobacterium tuberculosis. Estudio multicentrico en el área de Barcelona.
Med Clin (Barc), 115 (2000), pp. 493-498
[21.]
V. Ausina, M. Riutort, B. Vinado, J.M. Manterola, J. Ruiz Manzano, C. Rodrigo, et al.
Prospective study of drug-resistant tuberculosis in a Spanish urban population including patients at risk for HIV infection.
Eur J Clin Microbiol Infect Dis, 14 (1995), pp. 105-110
[22.]
M. Arévalo, J. Solera, D. Cebrián, J. Bartolome, P. Robles.
Risk factors associated with drug-resistant Mycobacterium tuberculosis in Castilla-La-Mancha (Spain).
Eur Respir J, 9 (1996), pp. 274-278
Copyright © 2003. Sociedad Española de Neumología y Cirugía Torácica
